Blog | HemaCare

HemaCare Apheresis Materials Aid COVID-19 Vaccine Clinical Trial

Oct 12, 2021 10:30:00 AM / by Nancy Andon, MSc posted in Apheresis, T Cells

0 Comments

Researchers involved in the clinical investigation of a new COVID-19 vaccine cited using HemaCare healthy donor starting materials for their study.

The scientists, most of whom work at ImmunityBio in Culver City, CA, are conducting a Phase 1 clinical trial for their new dual-antigen COVID-19 vaccine. [1]

Read More

HemaCare T Cells Support Study on Cell Therapy Consistency

Oct 5, 2021 10:30:00 AM / by Nancy Andon, MSc posted in Leukopak, Cancer, T Cells

0 Comments

A new publication by scientists at the Cell and Gene Therapy Catapult in the UK cites the use of HemaCare-sourced CD3+ T cells for their cancer immunotherapy research.

The successful commercialization of gene-modified cell therapies relies in part on being able to manufacture a consistent product. Many cell and gene therapy developers use lentiviral vector delivery systems to impart the therapeutic gene modifications necessary to making their therapies effective.

Read More

HemaCare PBMCs used for 3D Anti-Tumor Discovery Platform

Sep 28, 2021 10:30:00 AM / by Nancy Andon, MSc posted in Cryopreservation, PBMCs, T Cells, Immunotherapy (Immunology)

0 Comments

An independent publication cites the use of HemaCare-sourced PBMC as starting material for an assay designed to screen for factors that enhance anti-tumor cytotoxic T cell activity. [1]

The paper, published in the renowned scientific journal Nature, reports the study results of a scientific team working at Novartis in San Diego. Their goal is to develop a discovery platform that more closely mimics the in-vivo tumor microenvironment.

Read More

Brain Cancer Vaccine Passes Phase I Human Trial

Sep 21, 2021 11:00:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, T Cells

0 Comments

The vaccine was designed to assist a patient’s immune system target brain tumors more effectively and efficiently.

Gliomas are brain cancers that are considered rare disorders that affect 6.6 out of 100,000 individuals yearly worldwide.

Read More

Cancer CAR T Cell Therapy Adapted to Help Fight Threatening Fungal Infections

Sep 14, 2021 10:00:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, CAR-T, T Cells, Immunotherapy (Immunology)

0 Comments

Cryptococcus fungi infections can be fatal as the immune system struggles to fight off the invaders, but through immunotherapy called CAR T cell therapy, researchers are seeing positive results.

Cryptococcosis, a systemic fungal infection, is caused by the polysaccharide encapsulated yeasts Cryptococcus gatti and Cryptococcus neoformans. The disease can cause pneumonia and meningitis, as well as pathology in other tissues.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts